AVALON PHARMA

Middle East Pharmaceutical Industries Company

4016StocksTadawulHealthcare

Financials

1-5

	CurrentMar 10, 2026	2025Dec 31, 2025	2024Dec 31, 2024	2023Dec 31, 2023	2022Dec 31, 2022
Market & Price
Market Capitalization	1.97B	2.22B	2.44B	—	—
Market Cap Growth	-26.1%	-8.7%	—	—	—
Enterprise Value	1.99B	2.27B	2.50B	—	—
Last Close Price	98.25	111.20	119.61	—	—
Valuation Multiples
Forward PE (Next 12M Est.)	16.48	20.16	24.86	—	—
PE Ratio	20.26	22.93	30.51	—	—
PS Ratio	4.27	4.83	6.18	—	—
PB Ratio	4.72	5.34	6.62	—	—
P/TBV Ratio	5.55	6.29	7.67	—	—
P/FCF Ratio	26.65	30.16	111.20	—	—
P/OCF Ratio	22.19	25.12	73.65	—	—
EV/Sales Ratio	4.33	4.92	6.33	—	—
EV/EBITDA Ratio	16.74	19.03	25.19	—	—
EV/EBIT Ratio	18.65	21.20	27.95	—	—
EV/FCF Ratio	27.05	30.74	113.93	—	—
Leverage & Capital
Debt / Equity Ratio	0.15	0.15	0.17	0.20	0.30
Debt / EBITDA Ratio	0.54	0.54	0.64	0.73	1.11
Debt / FCF Ratio	0.87	0.87	2.89	0.86	1.44
Net Debt / Equity Ratio	0.07	0.07	0.11	0.15	0.22
Net Debt / EBITDA Ratio	0.25	0.25	0.41	0.55	0.80
Net Debt / FCF Ratio	0.40	0.40	1.85	0.65	1.04
Efficiency & Liquidity
Asset Turnover	0.82	0.82	0.80	0.76	0.70
Inventory Turnover	1.77	1.77	1.68	1.44	1.37
Quick Ratio	2.24	2.24	1.85	1.49	1.36
Current Ratio	3.13	3.13	2.65	2.36	2.22
Returns & Yields
Return on Equity (ROE)	+24.7%	+24.7%	+23.7%	+22.4%	+21.7%
Return on Assets (ROA)	+11.9%	+11.9%	+11.4%	+10.8%	+10.1%
Return on Invested Capital (ROIC)	+23.3%	+23.4%	+21.7%	+20.6%	+18.8%
Return on Capital Employed (ROCE)	+22.9%	+22.9%	+22.7%	+23.4%	+22.3%
Earnings Yield	+4.9%	+4.4%	+3.3%	—	—
FCF Yield	+3.8%	+3.3%	+0.9%	—	—
Dividend Yield	+2.5%	—	+1.7%	—	—
Payout Ratio	+48.4%	+48.4%	+18.8%	+54.7%	+61.1%
Total Shareholder Return	+2.5%	—	+1.7%	—	—

1-5

	CurrentMar 10, 2026	2025Dec 31, 2025	2024Dec 31, 2024	2023Dec 31, 2023	2022Dec 31, 2022
Market & Price
Market Capitalization	1.97B	2.22B	2.44B	—	—
Market Cap Growth	-26.1%	-8.7%	—	—	—
Enterprise Value	1.99B	2.27B	2.50B	—	—
Last Close Price	98.25	111.20	119.61	—	—
Valuation Multiples
Forward PE (Next 12M Est.)	16.48	20.16	24.86	—	—
PE Ratio	20.26	22.93	30.51	—	—
PS Ratio	4.27	4.83	6.18	—	—
PB Ratio	4.72	5.34	6.62	—	—
P/TBV Ratio	5.55	6.29	7.67	—	—
P/FCF Ratio	26.65	30.16	111.20	—	—
P/OCF Ratio	22.19	25.12	73.65	—	—
EV/Sales Ratio	4.33	4.92	6.33	—	—
EV/EBITDA Ratio	16.74	19.03	25.19	—	—
EV/EBIT Ratio	18.65	21.20	27.95	—	—
EV/FCF Ratio	27.05	30.74	113.93	—	—
Leverage & Capital
Debt / Equity Ratio	0.15	0.15	0.17	0.20	0.30
Debt / EBITDA Ratio	0.54	0.54	0.64	0.73	1.11
Debt / FCF Ratio	0.87	0.87	2.89	0.86	1.44
Net Debt / Equity Ratio	0.07	0.07	0.11	0.15	0.22
Net Debt / EBITDA Ratio	0.25	0.25	0.41	0.55	0.80
Net Debt / FCF Ratio	0.40	0.40	1.85	0.65	1.04
Efficiency & Liquidity
Asset Turnover	0.82	0.82	0.80	0.76	0.70
Inventory Turnover	1.77	1.77	1.68	1.44	1.37
Quick Ratio	2.24	2.24	1.85	1.49	1.36
Current Ratio	3.13	3.13	2.65	2.36	2.22
Returns & Yields
Return on Equity (ROE)	+24.7%	+24.7%	+23.7%	+22.4%	+21.7%
Return on Assets (ROA)	+11.9%	+11.9%	+11.4%	+10.8%	+10.1%
Return on Invested Capital (ROIC)	+23.3%	+23.4%	+21.7%	+20.6%	+18.8%
Return on Capital Employed (ROCE)	+22.9%	+22.9%	+22.7%	+23.4%	+22.3%
Earnings Yield	+4.9%	+4.4%	+3.3%	—	—
FCF Yield	+3.8%	+3.3%	+0.9%	—	—
Dividend Yield	+2.5%	—	+1.7%	—	—
Payout Ratio	+48.4%	+48.4%	+18.8%	+54.7%	+61.1%
Total Shareholder Return	+2.5%	—	+1.7%	—	—